Treating cancer by targeting a weakness

New England Journal of Medicine

Volumn 353, Issue 9, 2005, Pages 949-950

  Brody, Lawrence C ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ERLOTINIB; GEFITINIB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLY(ADP RIBOSE)POLYMERASE 1, MOUSE; POLY(ADP-RIBOSE)POLYMERASE-1, MOUSE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DNA DAMAGE; DNA REPAIR; ENZYME ACTIVITY; GENE MUTATION; GENE TARGETING; HUMAN; IONIZING RADIATION; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH; WILD TYPE; XENOGRAFT; ANIMAL; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENETICS; MOUSE; NEOPLASM; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; DNA DAMAGE; DNA REPAIR; GENES, BRCA1; GENES, BRCA2; MICE; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 24044509816     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMcibr052331     Document Type: Article

References (3)

1. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-7.
2. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
3. Conde C, Mark M, Oliver FJ, Huber A, de Murcia G, Menissierde Murcia J. Loss of poly(ADP-ribose) polymerase-1 causes increased tumour latency in p53-deficient mice. EMBO J 2001;20:3535-43.